| Entries |
| Document | Title | Date |
|---|
| 20080200537 | Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis - The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma. | 08-21-2008 |
| 20080207745 | Orally-absorbed formulation for paromomycin - A composition for oral treatment of visceral leishmaniasis comprises paromomycin and a permeation enhancer that increases oral bioavailability of the paromomycin to at least 20%. | 08-28-2008 |
| 20080221202 | STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS - The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor. | 09-11-2008 |
| 20080234361 | Pharmaceutical Compositions, Methods of Formulation Thereof and Methods of Use Thereof - A pharmaceutical composition including a physiologically effective amount of a mixture of conjugated fatty acid(s) and polyphenol(s) is disclosed. Methods of formulation are further disclosed. Trienoic acids such as punicic acid are employed in exceptionally preferred embodiments of the invention. The invention has utility in management/treatment of a wide range of clinical conditions including, but not limited to, obesity, diabetes, cancer and heart disease. | 09-25-2008 |
| 20080280974 | Spiro compounds for treatment of inflammatory disorders - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: | 11-13-2008 |
| 20080287525 | Pharmaceuticals for treating or preventing oral diseases - The present invention discloses Mulberrofuran G, a method of extracting Mulberrofuran G, as well as various uses of Mulberrofuran G in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses. | 11-20-2008 |
| 20080287526 | Pharmaceuticals for treating or preventing oral diseases - The present invention discloses a new compound of formula (I), a method of extracting the new compound, as well as various uses of the new compound in manufacturing antibacterial medicaments or oral care products or for other antibacterial uses. | 11-20-2008 |
| 20080300299 | Application of Eriocalyxin B in the Manufacture of Medicaments For Treating Leukemia - The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from getting into the nucleus in order to inhibition NF-κB pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation. | 12-04-2008 |
| 20080306139 | Antibiotic Compounds - Fermentation of a nutrient medium with a eubacterium | 12-11-2008 |
| 20080306140 | Isoflavonoid Dimers - Novel compounds based on phenyl-substituted naphtho[1,2-g]chrysene compounds (A) are described. The compounds are obtainable by dimerisation of 3-phenylchroman (isoflavonoid) ring systems (B). Methods of synthesis of the novel dimeric compounds, compositions containing same and use of the dimers as therapeutic agents are also described. | 12-11-2008 |
| 20090082427 | Composition comprising wortmannin and its topical use for reducing human hair growth - A cosmetic and therapeutic method for reducing human hair growth comprises selecting an area of skin from which reduced hair growth is desired and applying to the area of skin a composition comprising wortmannin in an amount effective to reduce hair growth. | 03-26-2009 |
| 20090118356 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS - Compounds of Formulas I-II are described, | 05-07-2009 |
| 20090131512 | Inhibition of type I in IFN production - The invention provides methods for decreasing type I IFN production by human plasmacytoid dendritic cells in response to TLR activation. | 05-21-2009 |
| 20090137661 | PLANT DERIVED COMPOUNDS AND COMPOUND FORMULAE CONTAINING THE SAME FOR THE TREATMENT OF CERVICAL CANCER - A composition for reducing the activity of a cervical cancer cell is provided. The composition includes at least one of the following compounds: isopsoralen, triptolide, baicalein, gallic acid, quercetin, gossypol-acetic acid, baicalin, berberine hydrochloride, and derivatives thereof in a sufficient amount to reduce the activity of the cervical cancer cell in the subject. | 05-28-2009 |
| 20090156661 | Compositions and Methods for Treatment and Prevention of Metabolic Syndrome and its Associated Conditions with Combinations of Flavonoids, Liminoids and Tocotrienols - The present invention is directed to compositions and methods for the treatment and/or prevention of metabolic syndrome and its associated conditions, such as insulin resistance, which involve using a combination composition of limonoids, flavonoids and tocotrienols. | 06-18-2009 |
| 20090163577 | METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS - The cytotoxic natural product gambogic acid (GA) competes for BH3 peptide binding sites on several anti-apoptotic members of the Bcl-2 family of proteins and neutralizes the ability of these proteins to suppress release of apoptogenic proteins from isolated mitochondria. Structure-function analysis of GA using analogs suggested a general correlation between BH3 competition and cytoxicity activity. Compositions and methods are provided for using GA and its derivatives for treating cancer and for discovering other compounds that are useful for treating cancer through their interaction with Bcl-2-family proteins. | 06-25-2009 |
| 20090221690 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof - Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti-osteoporosis (bone forming) activity of | 09-03-2009 |
| 20090258938 | Administration of 6'-ethyl lepimectin, 6' -methyl lepimectin or derivatives thereof for treating dermatological disorders in humans - 6′-ethyl lepimectin, 6′-methyl lepimectin or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 10-15-2009 |
| 20090264517 | Milbemycin compounds and treatment of dermatological disorders in humans therewith - Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 10-22-2009 |
| 20100016417 | ELASTIN PROTECTIVE POLYPHENOLICS AND METHODS OF USING THE SAME - Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers. | 01-21-2010 |
| 20100022630 | Method of treatment using fatty acid synthesis inhibitors - The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases. | 01-28-2010 |
| 20100048688 | DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING CARNOSOL AND/OR ROSMANOL AND THEIR USES - The present invention refers to carnosol and rosmanol for use (as medicament) in the treatment of a disorder connected to reduced neurotransmission, cognitive dysfunction and/or symptoms caused by headache and/or migraine, as well as to dietary and pharmaceutical compositions and their uses. | 02-25-2010 |
| 20100056617 | Role of limonoid compounds as neuroprotective agents - Disclosed herein are neuroprotective compounds. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of neurodegenerative conditions are provided. | 03-04-2010 |
| 20100120902 | STANDARIZED BIOACTIVE HERBAL EXTRACTS - The present invention relates to standardized extracts of | 05-13-2010 |
| 20100137420 | Methods and Compositions for Diagnosis and Treatment of Multiple Sclerosis - Biological markers for multiple sclerosis, and their use in the diagnosis and prognosis of the disease, are described. Also described are methods for treating multiple sclerosis by administering an inhibitor of cathepsin B activity or a neuroprotective composition comprising a modified terpenoid compound. Also described are isolated polypeptide biomarkers, polynucleotides encoding the polypeptide biomarkers, and antibodies that bind specifically to the polypeptide biomarkers. Further described are kits that include the above-mentioned isolated polypeptide biomarkers, the polynucleotides encoding them, or specific antibodies against the polypeptide biomarkers. | 06-03-2010 |
| 20100137421 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE - Provided herein are compounds that are inducers of apoptosis activators of caspases and pharmaceutically acceptable derivatives thereof. Also provided are methods of synthesis of the compounds and methods for treatment of diseases in which there is uncontrolled cell growth and spread of abnormal cells, such as cancers, by administering the compounds. | 06-03-2010 |
| 20100137422 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME - Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 06-03-2010 |
| 20100168219 | Chronic inflammation and transplantation - Neutrophils (PMN) can migrate along gradients of chemoattractants across endothelial monolayers to sites of inflammation and infection. This chemotaxis through endothelial cell borders is involved in several acute and chronic inflammatory diseases, however our understanding of the role of endothelial second messengers in the regulation of leukocyte emigration is still incomplete. We investigated this using an in vitro model of neutrophil migration across human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells (HMECs) on cell culture inserts. We report that activation of endothelial protein kinase C (PKC) by both phorbol myristate acetate (PMA) and Bryostatin-1 (a potent PKCδ and c activator) can completely abolish neutrophil migration mediated by both endothelial TNF-α stimulation and a leukotriene B4 (LTB | 07-01-2010 |
| 20100227918 | STREPTOMYCES-DERIVED ANTIMICROBIAL COMPOUND AND METHOD OF USING SAME AGAINST ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates to a novel antimicrobial compound of lactoquinomycin that is highly effective against many antibiotic-resistant gram-positive bacteria; namely, methicillin-resistant and vancomycin-resistance | 09-09-2010 |
| 20100234453 | PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM - Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular phenanthrenequinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient. | 09-16-2010 |
| 20100317727 | ROSEMARY EXTRACTS, DIETARY AND PHARMACEUTICAL COMPOSTIONS CONTAINING THEM AND THEIR USES - The present invention refers to rosemary extracts for use as medicament for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions containing such rosemary extracts and their uses. | 12-16-2010 |
| 20100317728 | DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES - The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to V, for use as medicaments for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions and their uses. | 12-16-2010 |
| 20100331398 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS - Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof. | 12-30-2010 |
| 20110003887 | TREATING ONCOGENIC RAS DRIVEN CANCERS - Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP-bound activated wildtype H and N Ras. L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway. | 01-06-2011 |
| 20110021615 | METHOD OF PROTECTING PLANT(S) AND A PROCESS THEREOF - The present invention relates to a method of treating plant(s) against larval pests by the use of terreulactone. It also relates to a process for producing meroterpenoid from fungus | 01-27-2011 |
| 20110039923 | NOVEL STANDARDIZED COMPOSITION, METHOD OF MANUFACTURE AND USE IN THE RESOLUTION OF RNA VIRUS INFECTION - The present disclosure is in relation to antiviral preparations obtained from plant sources namely Cinnamon, | 02-17-2011 |
| 20110077293 | GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 03-31-2011 |
| 20110112181 | POLYPHENOL COMPOUNDS WITH MODULATING NEUROTRANSMITTER RELEASE - Disclosed is a composition for modulating the release of a neurotransmitter, which includes naturally extracted polyphenols as an active ingredient. The disclosed composition suppresses the formation of a SNARE complex, thereby modulating the release of a neurotransmitter, and thus can be used as a modulator for a reaction within a cell related to the SNARE complex. Such an inhibitor of the SNARE complex formation can be used as a composition for reducing wrinkles and relieving pain. | 05-12-2011 |
| 20110144192 | Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria - Method for modulating or controlling sodium channel current of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell. | 06-16-2011 |
| 20110160296 | PREPARATION OF 6-OXA-8ALPHA-STEROID ESTROGEN ANALOGUES - A NEW GROUP OF UNNATURAL ESTROGENS AND THEIR USE IN MEDICINE - The invention is related to the area of new 6-Oxa-8α-steroid estrogen analogues and the synthesis of these new biological active steroid estrogen analogues, namely, to the preparation of 6-oxa-8α-steroid estrogens and their use as estrogen receptor modulators. These new estrogen analogues are ligands for estrogen receptors and as such may be useful for the treatment and prevention of a variety of conditions related to estrogen functioning. These conditions include bone and cartilage disorders, increased levels of LDL cholesterol, cardiovascular diseases, impairment of cognitive function, cerebral degeneration disorders, endometriosis and other types of inflammation, the metabolic syndrome, and cancer, in particular of the breast, uterus and prostate. | 06-30-2011 |
| 20110166216 | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma - There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof. | 07-07-2011 |
| 20110213023 | METHOD FOR INHIBITING PRODUCTION OF CYTOKINES OF T HELPER CELL TYPE II AND/OR INHIBITING PRODUCTION OF CHEMOKINES USING BRAZILIN - A method for inhibiting the production of cytokines of T helper cell type II (Th2 cell) and/or inhibiting the production of chemokines in a mammal is provided, wherein the method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound of formula (I), pharmaceutically acceptable salts and esters of the compound, and combinations thereof: | 09-01-2011 |
| 20110224289 | COMPOUNDS OF THE PTEROCARPANQUINONE FAMILY, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION CONTAINING THE NEW COMPOUNDS OF THE PTEROCARPANQUINONE FAMILY, USES AND THERAPEUTIC METHOD - This invention belongs to the chemical-pharmaceutical field. New compounds of pterocarpanquinone family presented in formula (I) according to this invention are capable to be activated by reduction generating alkylating species intracellularly. It presents selective cytotoxic effects particularly on mammalian human and nonhuman cells that divide constantly and are useful in treating diseases and dysfunctions related to the phenomenon of undesired cell proliferation. Such compounds are also effective for the treatment of diseases or dysfunctions related to high levels of TNF-α in human and nonhuman mammals. | 09-15-2011 |
| 20110251270 | COMPOUNDS AND METHODS FOR REPELLING BLOOD-FEEDING ARTHROPODS AND DETERRING THEIR LANDING AND FEEDING - This invention relates to a group of compounds for repelling blood-feeding ectoparasitic arthropods, and a method of deterring their landing and feeding on animals including humans, by applying in one or more formulations compounds that incorporate one or more sulfide and one or more hydroxyl groups to the skin, clothing or environment of animals, including humans. A method of repelling and deterring landing and feeding by blood-feeding arthropods on an animal by applying in effective amount one or more compounds that incorporate alkyl sulfide and alcohol moieties, or alkyl sulfide and amide moieties, or alkyl sulfide and amide moieties to the skin, clothing or environment of an animal. | 10-13-2011 |
| 20110263693 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS - Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hsρ90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia. | 10-27-2011 |
| 20120004295 | ADMINISTRATION OF 6'-ETHYL LEPIMECTIN, 6'-METHYL LEPIMECTIN OR DERIVATIVES THEREOF FOR TREATING DERMATOLOGICAL DISORDERS IN HUMANS - 6′-ethyl lepimectin, 6′-methyl lepimectin or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 01-05-2012 |
| 20120101151 | COMBINATION THERAPY AND USES THEREOF FOR TREATMENT AND PREVENTION OF PARASITIC INFECTION AND DISEASE - The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., | 04-26-2012 |
| 20120149766 | DIETARY AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SAGE EXTRACT CONTAINING A MIXTURE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES - The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to V, for use as medicaments for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions and their uses. | 06-14-2012 |
| 20120149767 | Connection Device for a Submersible Connector - The invention relates to a device ( | 06-14-2012 |
| 20120309818 | CHRONIC INFLAMMATION AND TRANSPLANTATION - Embodiments of the present invention feature methods for treating inflammatory disease and transplantation characterized in that it includes: (i) the incubation of organs with one or more Bryostatin-1 derivatives under conditions which permits vascular exposure to these compounds prior to or immediately following organ ‘harvesting’, and (ii) intravenous, transdermal, intraperitoneal, intra-alveolar instillation of Bryostatin-1 in vivo during active disease, or during periods of disease remission and (iii) prophylactic administration of Bryostatin-1 to limit the development of GVHD. | 12-06-2012 |
| 20120309819 | Acid-Labile Lipophilic Prodrugs of Cancer Chemotherapeutic Agents - The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof. | 12-06-2012 |
| 20130041022 | Glyceollins Suppress Androgen-Responsive Prostate Cancer - The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due to an inhibition on G1/S progression and correlated with an up-regulation of cyclin-dependent kinase inhibitor A1 and B1 mRNA and protein levels. By contrast, genistein only up-regulates cyclin-dependent kinase inhibitor A1. In addition, glyceollin treatments led to down-regulated mRNA levels for androgen responsive genes. In contrast to genistein, this effect of glyceollins on androgen responsive genes appeared to be mediated through modulation of an estrogen- but not androgen-mediated pathway. Hence, the glyceollins exerted multiple effects on LNCaP cells that may be considered cancer preventive and the mechanisms of action appeared to be different from other soy-derived phytochemicals. | 02-14-2013 |
| 20130085177 | COSMETIC COMPOSITION BASED ON ELLAGIC ACID OR A DERIVATIVE THEREOF AND ON A PARTICULAR MIXTURE OF SURFACTANTS - The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) from 0.2% to 10% by weight of one or more compounds selected from ellagic acid, ethers thereof, ellagic acid salts and ellagic acid ether salts, and mixtures thereof, and (ii) a system of surfactants selected from the following mixtures comprising: (iii) one or more anionic surfactants selected from ethoxylated alkyl sulphates, the corresponding acids, and mixtures thereof, and (iv) one or more anionic surfactants different from the abovementioned anionic surfactant(s) (iii), and (v) one or more anionic surfactants and (vi) one or more amphoteric or zwitterionic surfactants, in a weight ratio of the amount of anionic surfactant(s) to the amount of amphoteric or zwitterionic surfactant(s) of greater than 3. The invention also relates to a cosmetic treatment method using such a composition and to the use of said composition for washing keratin fibres. | 04-04-2013 |
| 20130085178 | COMPOSITION FOR TREATING BONE DISEASE COMPRISING A GLYCEOLLIN AS AN ACTIVE INGREDIENT - A method for preventing or treating a bone disease, includes administering to a patient having the bone disease a pharmaceutical composition comprising glyceollin as an active ingredient. The active ingredient, glyceollin promotes degradation of the Runx2 protein in osteoblasts and inhibits the mRNA expression of Rankl in osteoblasts to prevent the differentiation of osteoclasts. Furthermore, glyceollin is capable of ameliorating osteoporosis in animal models for osteoporosis. The composition promises drug or food for prevention or treatment of not only osteoporosis but also bone diseases caused by cancer metastatic to the bone. | 04-04-2013 |
| 20130090377 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition for activating mitochondria comprising coumestrol or a bean extract containing coumestrol. | 04-11-2013 |
| 20130109746 | COMPOSITION COMPRISING ELLAGIC ACID AND A PARTICULAR CATIONIC SURFACTANT, AND COSMETIC USE THEREOF | 05-02-2013 |
| 20130131156 | Cancer Treatment with Wortmannin Analogs - Provided herein are certain therapeutically effective dosing regimens for treatment of cancers with wortmannin analogs. | 05-23-2013 |
| 20130131157 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 05-23-2013 |
| 20130137760 | GAMBOGIC AMINE, A SELECTIVE TRKA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 05-30-2013 |
| 20130203842 | PESTICIDE AND A METHOD OF CONTROLLING A WIDE VARIETY OF PESTS - A pesticidal composition including at least one substance derived from | 08-08-2013 |
| 20130281522 | METHODS FOR ALZHEIMER'S DISEASE TREATMENT AND COGNITIVE ENHANCEMENT - The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s). | 10-24-2013 |
| 20130303602 | NOVEL PTEROCARPAN COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE OR COMPLICATION THEREOF, OR FOR ANTIOXIDANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits α-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity. | 11-14-2013 |
| 20130303603 | METHOD OF PREPARING A MUSCADINE POMACE EXTRACT - Disclosed herein is a method of producing a muscadine pomace extract. The method can include combining a bronze muscadine pomace extract with a purple muscadine pomace extract to produce a muscadine pomace extract, wherein the ratio of bronze muscadine pomace extract to purple muscadine pomace extract ranges from 0.1 to 10 (weight to weight), such as from 0.3 to 3 (weight to weight), and the muscadine pomace extract has a polyphenol content of at least 2%. Also disclosed herein is a muscadine pomace extract for use as an antioxidant, such as for use as an anti-aging supplement. The composition can include a muscadine ( | 11-14-2013 |
| 20130338219 | Terpenoid Spiro Ketal Compounds with LXR Agonists Activity, Their Use and Formulations with Them - The invention relates to compositions and methods (with regard to animals and humans) for utilizing an extract and/or one or more natural spiro triterpenoids and derivatives thereof alone or as a supplement. Certain materials utilized are from the blazeispirol family, obtainable from | 12-19-2013 |
| 20140011868 | Use of Simalikalactone E as an Anticancer Agent - The invention relates to Simalikalactone E (SkE) to be used for preventing and/or treating cancers. | 01-09-2014 |
| 20140066496 | Composition and Methods for Anti-Macrofouling Treatment of Polymers - There is herein provided a composition comprising azadirachtin, preferably neem oil, and methods of use thereof for inhibiting macrofouling on a polymer in an aquatic environment. | 03-06-2014 |
| 20140187620 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 07-03-2014 |
| 20140187621 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 07-03-2014 |
| 20140187622 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 07-03-2014 |
| 20140194498 | POLYISOPRENYLATED TETRACYCLIC XANTHONE WITH ANTICANCER ACTIVITY - A novel polyisoprenylated tetracyclic xanthone, named garciesculentone B, isolated from | 07-10-2014 |
| 20140235707 | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO ERIBULIN - The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject. | 08-21-2014 |
| 20140275233 | ACTIVATED SOY POD FIBER - The present invention provides, among other things, compositions and methods of manufacturing edible soy pod fiber comprising glyceollins. In some embodiments, methods of treating overweight, obesity, prediabetes, diabetes, or gastrointestinal dysbiosis in a subject are provided comprising orally administering a composition or food product comprising edible soy pod fiber comprising glyceollins. | 09-18-2014 |
| 20140275234 | COMPOSITIONS AND METHODS OF USING CRYSTALLINE FORMS OF WORTMANNIN ANALOGS - Provided herein are novel crystalline forms of Compound 1. Also provided herein are compositions and methods of uses for the crystalline forms of Compound 1. | 09-18-2014 |
| 20140303242 | Sparstolonin B Based Pharmaceutical Agent to Treat Pathological Angiogensis - Anti-angiogenesis methods and compositions are described. The anti-angiogenic effect is provided by application of sparstolonin B or a derivative thereof to endothelial cells. The sparstolonin B or derivative thereof can inhibit angiogenesis by targeting endothelial cell cycle progression, cell migration, and chemotaxis. | 10-09-2014 |
| 20140343135 | METHOD FOR OBTAINING AN EXTRACT RICH IN ELLAGIC ACID TANNINS FROM FRUITS THAT CONTAIN THESE COMPOUNDS, AND RESULTING EXTRACT - A biotechnology process that employs membrane technology for obtaining an extract rich in tannins of ellagic acid from blackberries ( | 11-20-2014 |
| 20140364490 | 1-OXO/ACYLATION-14-ACYLATED ORIDONIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - The present invention relates to the fields of natural medicine and medicinal chemistry, and more particularly to a 1-oxo/acylated-14-acylated oridonin derivative of a general formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the compounds, a pharmaceutical composition comprising the compounds, and application thereof in preparation of antitumor drugs. | 12-11-2014 |
| 20140371303 | COMPOSITIONS AND METHODS FOR GLYCEMIC CONTROL OF SUBJECTS WITH IMPAIRED FASTING GLUCOSE - Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol. | 12-18-2014 |
| 20150045422 | Influenza treatment using targeted transient ribosomal inhibition - Novel methods are presented for treating Influenza by using Targeted Transient Ribosomal Inhibition (TTRI), with TTRI drugs administered by inhalation, to silence expression of every protein underlying the etiology and pathology of the influenza infection, and without adversely effecting normal cells in the lungs. The therapeutic effect is dual Antiviral and Anti-Inflammatory activity which is localized to the lungs. Pulmonary TTRI for influenza silences expression of all 10 influenza viral proteins and de novo synthesis of cytokines and leukotrienes produced in the lungs. By targeting ribosomes, TTRI is insensitive to viral mutations or human alterations to the virus. TTRI provides an off-the-shelf solution for preventing mortality from any strain of influenza. | 02-12-2015 |
| 20150105454 | Sparstolonin B Based Pharmaceutical Agent for Neuroblastoma Treatment - Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb | 04-16-2015 |
| 20150336977 | Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same - The present invention provides new coumestans compounds and processes for the preparation of coumestans, pharmaceutical compositions having a coumestan as an active pharmaceutical ingredient, and methods of utilizing coumestans as selective estrogen receptor modulators (SERMs) for treating estrogen dependent diseases such as breast cancer. | 11-26-2015 |
| 20160067209 | PTEROCARPAN COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE OR COMPLICATION THEREOF, OR FOR ANTIOXIDANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits α-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity. | 03-10-2016 |
| 20160089357 | USE OF FRACTIONATED PRODUCTS OF GAMBOGE RESIN IN THE TREATMENT OF CANCER, PAIN, AND INFLAMMATION - Disclosed herein are seventeen new compounds and five fractionated products obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds and the five fractionated products have activities in inhibiting the growth of tumor/cancer cells. In addition, the acetone-extracted product of gamboge resin and the five fractionated products obtained therefrom have analgesic and anti-inflammatory effects. | 03-31-2016 |
| 20160089359 | COMPOSITION FOR PREVENTING OR TREATING CLIMACTERIC SYMPTOMS COMPRISING SOYBEAN EXTRACT COMPRISING COUMESTROL AS AN ACTIVE INGREDIENT - The present invention relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, preventing or treating a climacteric disease, or preventing or improving a climacteric skin symptom comprising a germinated and fermented soybean extract comprising coumestrol as an active ingredient. | 03-31-2016 |
| 20190142785 | Compound that Inhibits Binding of Influenza-Virus PB Subunit to RNA Cap | 05-16-2019 |
| 20190144462 | METHODS OF MAKING LOW ODOR CHOLINE SALTS OF AN ORGANIC COMPOUND | 05-16-2019 |
